CompletedNot Applicable

Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty

Taiwan150 participantsStarted 2023-02-01

Plain-language summary

Venous thromboembolism is a serious complication after total hip replacement (THR) and total knee replacement (TKR). Previous studies have reported the incidence of both asymptomatic and symptomatic deep vein thrombosis (DVT) after TKR were higher in Taiwan than other countries in Asia. Therefore, the usage of prophylactic antithrombotics should be considered. The efficacy and safety of Xarelto (Rivaroxaban) for preventing venous thromboembolism has been proved. However, there is a lack of study using prospective design to evaluate the efficacy and safety of Xarelto after THR and TKR for Taiwanese. In this study, the investigators use a randomized controlled trial design comparing the incidence of DVT, pulmonary embolism, and complications between intervention and control groups.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Undergo total knee replacement or total hip replacement Exclusion Criteria: * Recent antithrombotics use * A history of a coagulopathy * Recent thromboembolic disease * Preoperative deep vein thrombosis screening presents positive * Age below 20

What they're measuring

Deep Vein Thrombosis

Timeframe: Up to 3 months after THR and TKR

Pulmonary Embolism

Timeframe: Up to 3 months after THR and TKR

Trial details

NCT IDNCT05449327

SponsorChiayi Christian Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-21

Results submitted2026-03-05

View on ClinicalTrials.gov More Venous Thromboembolism trials